Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Spectrum Hopes For Synergies With Allos Acquisition Amid Phase III Setback

This article was originally published in The Pink Sheet Daily

Executive Summary

Spectrum issued a tender offer of $1.82 per share for Allos Therapeutics on the same day that it announced the Phase III failure of its bladder cancer drug.

You may also be interested in...



Spectrum Failed To Heed FDA Advice On Apaziquone, And Is Paying The Price

FDA's original advice against NDA submission foreshadows advisory committee conclusion that substantial evidence of efficacy in bladder cancer not demonstrated by two negative trials and a post hoc pooled analysis.

Spectrum's Apaziquone: Can Two Failed Studies Lead To An Approval?

Spectrum says 6% reduction in bladder cancer recurrence is clinically meaningful even though studies failed their primary endpoint; FDA advisory committee also will weigh issues of data pooling and timing of drug administration.

Spectrum Puts Its Eggs In One Basket: Folotyn, Beleodaq To Share Confirmatory Trial

With Spectrum’s Beleodaq’s accelerated approval for peripheral T-cell lymphoma, FDA rolls Folotyn accelerated approval requirement into one post-marketing trial that will provide answers on both drugs – including which is better against standard of care.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL009864

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel